Citadel Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-450
| Closed | -$5.12K | – | 15869 |
|
|
2023
Q4 | $5.12K | Sell |
450
-40
| -8% | -$314 | ﹤0.01% | 13454 |
|
|
2023
Q3 | $1.98K | Buy |
490
+440
| +880% | +$3.26K | ﹤0.01% | 13778 |
|
|
2023
Q2 | $355 | Sell |
50
-2,580
| -98% | -$17.8K | ﹤0.01% | 14146 |
|
|
2023
Q1 | $19.6K | Buy |
2,630
+920
| +54% | +$7.74K | ﹤0.01% | 13085 |
|
|
2022
Q4 | $12.4K | Hold |
1,710
| – | – | ﹤0.01% | 13506 |
|
|
2022
Q3 | $17K | Sell |
1,710
-1,000
| -37% | -$18.7K | ﹤0.01% | 12139 |
|
|
2022
Q2 | $52K | Buy |
2,710
+1,030
| +61% | +$26.7K | ﹤0.01% | 11926 |
|
|
2022
Q1 | $84K | Sell |
1,680
-620
| -27% | -$32.1K | ﹤0.01% | 12443 |
|
|
2021
Q4 | $174K | Buy |
2,300
+1,010
| +78% | +$68.9K | ﹤0.01% | 12064 |
|
|
2021
Q3 | $102K | Sell |
1,290
-640
| -33% | -$64.3K | ﹤0.01% | 12845 |
|
|
2021
Q2 | $268K | Buy |
1,930
+440
| +30% | +$83.9K | ﹤0.01% | 11539 |
|
|
2021
Q1 | $312K | Sell |
1,490
-890
| -37% | -$178K | ﹤0.01% | 10764 |
|
|
2020
Q4 | $395K | Buy |
2,380
+120
| +5% | +$18.5K | ﹤0.01% | 8593 |
|
|
2020
Q3 | $384K | Buy |
+2,260
| New | +$326K | ﹤0.01% | 7734 |
|
Citadel Advisors's HARP Position: Q1 2024 in Review
Citadel Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 685,000 shares — an estimated $7.79M sold.
Citadel Advisors first reported a position in HARP in Q2 2020 and held it in 12 quarters. The position peaked at $7.79M in Q4 2023. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Citadel Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Citadel Advisors sold 685,000 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $7.79M.
- Citadel Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
- Citadel Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $7.79M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.